GCTK - Bathi resik saben saham (EPS TTM) GlucoTrack

The trailing twelve-month earnings per share for GlucoTrack, Inc. (GCTK) demonstrates the impact of sensor patent protection and the complexities of FDA certification. The value of -363.85 reflects this status, which is supported by the integration of AI applications with ear sensors. Stability in fundamental metrics is ensured by a staff of leading biosensor engineers, preventing the attrition of key developers from the company's core.

GlucoTrack, Inc. is currently commercializing non-invasive glucose monitoring systems, competing with medtech behemoths. This indicator represents the aggregate annual net income distributed per share. Investors utilize this metric to assess the actual efficiency of capital generation. By analyzing the trend of the rolling net income per share, one can judge the ability of sensor technologies to protect margins. The upward curve confirms the business's resilience against technological pressure from competitors.